dementia and parkinsonism
Conditions
Interventions
None listed
Sponsors
Leids Universitair Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Ability to undergo MRI scanning - For probable FTLD-tau: a clinical diagnosis of PSP, CBS or nfvPPA, or any clinical FTLD spectrum diagnosis with a proven MAPT mutation - For probable FTLD-TDP: a clinical diagnosis of svPPA or any clinical FTLD spectrum diagnosis with a proven GRN mutation or C9orf72 repeat expansion - For presymptomatic mutation carriers: a MAPT mutation, GRN mutation or a C9orf72 mutation withouth clinical sign of a FTLD spectrum phenotype (CDR 0) - For control subjects: no known neurological or psychiatric disorder
Exclusion criteria
Exclusion criteria: - Other neurological or psychiatric disorder that may affect cognitive functions, such as a brain tumour, multiple sclerosis or drug or alcohol abuse or use of psycho-active medications - CSF profile (β-amyloid, p-tau, t-tau) suggestive of AD pathology - Clinical dementia Rating Scale (CDR) score >1 - Contra-indication to undergo MRI - Contra-indication to undergo lumbar puncture
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Differences between patients with FTLD-TDP, patients with FTLD-tau in the symptomatic and presymptomatic stage and healthy controls in CSF and MRI measures for neuroinflammation and correlation with clinical measures at baseline and follow-up. | — |
Countries
Netherlands
Outcome results
None listed